Stock Market 16 December 2025

March 16, 2026, 2:59 PM EDT. Johnson & Johnson's (JNJ) investigational bladder cancer treatment, Erda-iDRS, met its primary safety endpoint in a Phase I study targeting non-muscle-invasive bladder cancer (NMIBC) with FGFR gene alterations, found in up to 70% of intermediate-risk and 40% of high-risk patients. The localized drug-delivery system releases erdafitinib directly into the bladder, limiting systemic side effects. Results showed an 89% complete response (CR) rate in intermediate-risk patients, with median CR duration around 18 months. High-risk patients saw median recurrence-free survival of 20 months and 83% survival at 12 months. The therapy was generally well-tolerated with mild to moderate adverse effects and no dose-limiting toxicities. Shares of JNJ rose 36.3% over six months, outperforming the 17.2% industry gain, as the company prepares for further development steps.